Autosomal dominant lateral temporal epilepsy (ADTLE) is a partial epilepsy caused by mutations in LGI1, a multidomain protein of unknown function. To begin to understand the biological function of LGI1, we have determined its pattern of glycosylation, subcellular expression and capacity for secretion. LGI1 is expressed as two different isoforms in the brain, and we show that the long isoform is a secreted protein, whereas the short isoform is retained in an intracellular pool. ADLTE-related mutants of the long form are defective for secretion and are retained in the endoplasmic reticulum and Golgi complex. Finally, we show that normal secreted LGI1 specifically binds to the cell surface of differentiated PC12 cells. We propose that LGI1 is a secreted factor important for neuronal development and that ADTLE is a disease that results from the loss of regulation in the protein available either extracellular or intracellularly.
INTRODUCTION
Autosomal dominant lateral temporal epilepsy (ADLTE, OMIM no. 600512) (also known by some authors as autosomal dominant epilepsy with auditory features) is a neurological disorder characterized by auditory auras and focal seizures affecting the lateral temporal lobe of the brain. The disease was mapped to a 3 cM locus on human chromosome 10 by linkage analysis (1, 2) . In 2002, Morante-Redolat et al. (3) and Kalachikov et al. (4) 
demonstrated that mutations in
LGI1 (leucine-rich glioma-inactivated 1) cause ADLTE. Numerous mutations have been found throughout the protein coding regions of this gene, but their effect on protein function is unknown. (3 -11) .
LGI1 was originally localized to the breakpoint of a balanced translocation between chromosomes 10 and 19 (tf10;19gfq24;13g) present in the glioblastoma cell line T98G (12) . Because LGI1 showed low expression levels in human high-grade glial tumor samples and glioblastoma cell lines compared with normal brain samples, it was proposed to act as a tumor suppressor (12) . However, more recent studies have challenged this view and concluded that LGI1 loss of function is unlikely to play a role in glial tumor progression (13) . The protein encoded by LGI1 consists of a signal peptide and three leucine-rich repeats flanked by two cysteine-rich regions in the N-terminal part of the protein.
Additionally, a novel domain composed of seven tandem repeats of 50 amino acids, termed EPTP repeats, was found in the C-terminal part of the protein. These EPTP repeats likely form a seven-bladed beta-propeller structure (14) . The EPTP repeat is also found in three paralogues of LGI1 (LGI2, LGI3 and LGI4) as well as in two otherwise unrelated genes (TNEP1 and VLGR1) and together, these constitute the EPTP superfamily (14, 15) .
The function of LGI1 remains unclear. Recent studies from Senechal et al. (16) have shown that LGI1 is a secreted protein, consistent with our earlier prediction (3) , and some studies have suggested that LGI1 is involved in regulation of cell movement, growth and survival (17, 18) . Interestingly, LGI4 has also been shown to be a secreted protein that may play a role in peripheral nerve myelination (19) , whereas Schulte et al. (20) have provided evidence that LGI1 is a membrane-associated protein that regulates the activity of the Kv1.1 voltage-dependent potassium channel subunit.
In this work, we confirm that LGI1 is a secreted glycoprotein even in neuronal-like cells and show that a truncated naturally occurring spliced isoform is retained within cells. We show that the secretion of the full-length isoform # The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org depends on the integrity of each of its domains and that disease-causing ADLTE mutations block LGI1 secretion. Moreover, we provide evidence for an LGI1 receptor on cell surfaces. Together, our data indicate that manifestation of ADLTE is related to defects in the LGI1 secretion.
RESULTS
The LGI1 isoforms are glycoproteins with different cellular fates Human LGI1-Flag LONG and LGI1-Flag SHORT , shown schematically in Figure 1A , were transiently transfected in HEK293T cells, the extracellular media were concentrated and the cell extracts were immunoprecipitated with anti-Flag monoclonal antibodies.
LGI1-Flag LONG was clearly present in both lysates and media, whereas LGI1-Flag SHORT was only detected in cell lysates, suggesting that only LGI1-Flag LONG was capable of being secreted (Fig. 1B) . Similar experiments were performed on T98G cells, a glioblastoma-derived cell line lacking LGI1 expression (Fig. 1B) , and on COS7 and CHO cells. In all cases, LGI1-Flag LONG accumulated in media, whereas LGI1-Flag SHORT did not, indicating that the secretion of LGI1-Flag LONG does not show cell-type specificity. In some instances, a minor band is observed in cell lysates over-expressing the LGI1-Flag LONG or the LGI1-Flag SHORT isoforms. The identity of such band has not been further investigated; therefore, we cannot exclude the possibility that LGI1 is being post-transcriptionally processed at a position close to the C-terminus end of the protein which is common to both isoforms. Finally, we tested the ability of LGI1 to be secreted on differentiated PC12 cells, a neuronallike cell type. As is shown in Figure 1B , NGF-differentiated PC12 cells are also capable of secreting LGI1-Flag LONG , but retaining LGI1-Flag SHORT as well as an ADLTE-causing mutation (LGI1-Flag 758delC ) (data not shown). In addition, to verify that the secretion was cell-line independent, we also tested the influence that the different tags used had on this process and found that the secretion of LGI1 was not altered by attaching a larger tag such as GFP at its C-terminus (data not shown). To confirm that accumulation of LGI1 in media reflects active secretion from living cells, pulse-chase analyses were performed. Figure 1C shows that HEK293T cells transfected with LGI1-Flag LONG and, 24 h later, labelled with 35 S-Cys/Met showed accumulation of radioactive LGI1 in media within 30 min. This time course suggests that LGI1 is actively secreted.
If LGI1 enters the secretory pathway, it is likely to undergo N-linked glycosylation. To test this, we performed PNGase F treatment of LGI1-Flag LONG and LGI1-Flag SHORT . Figure 2B shows that both isoforms undergo a substantial molecular weight shift when treated with PNGase F, suggesting that both become N-glycosylated in the endoplasmic reticulum. We introduced point mutations at three predicted Nglycosylation sites in the full-length isoform (LGI1-Flag LONG-N192Q/N277Q/N422Q
) and found that the protein produced no longer underwent a molecular weight shift when treated with PNGase F, indicating that some or all of these sites are required for N-glycosylation of the protein.
We also examined truncated forms of LGI1-Flag in this assay and found that a truncated protein lacking the LRR domain was sensitive to the PNGase F treatment, whereas a corresponding construct in which the glycosylation sites had been mutated to glutamic acid (LGI1-Flag DLRR-N277Q/N422Q ) was not (Fig. 2C) . If glycosylation sites in this construct were mutated individually (i.e. LGI1-Flag DLRR-N277Q and LGI1-Flag DLRR-N422Q ), the resulting proteins were sensitive to the PNGase F treatment. We also examined a construct in which the EPTP domain was deleted and, using a similar approach, found that a single potential N-linked glycosylation residue in the resulting product (LGI1-Flag DEPTP-N192Q ) conferred sensitivity to the PNGase F treatment. Together, these data indicate that N192Q, N277Q and N422Q are sites of N-linked glycosylation in LGI1.
We next assessed whether N-glycosylation of LGI1 was required for its secretion and evaluated the effect of the three potential N-glycosylation sites on the secretion of LGI1. For this, we compared the secretion of the normal protein to the triple mutant and to each of the single glycosylation mutants (LGI1-Flag N192Q , LGI1-Flag N277Q and LGI1-Flag N422Q ). Figure 2D shows that the triple mutant (LGI1-Flag LONG-N192Q/N277Q/N422Q ) was not secreted and that the secretion of the N192Q mutant was severely attenuated. 
Role of LGI1 domains in the secretion of the protein
To determine whether the LRR and EPTP domains were required for secretion, two artificial constructs, LGI1-Flag
LGI1-Flag DLRR , were transfected in HEK293T cells and their accumulation in media was assessed. Figure 3B shows that LGI1 lacking its LRR domain is efficiently secreted, although this is in contrast with the results of Senechal et al., and the constructs used in each work being not comparable. Whereas in this work our construct deleted the full LRR domain, including the flanking Cys-rich domains, in Senechal et al. the construct used in the same experiments maintained the Cys-rich domains; thus, it is possible that this construct behaves as a pathogenic mutation rather than as a wild-type protein. On the other hand, LGI1 lacking its EPTP domain is retained in the transfected HEK293T cells. We attempted to rescue LGI1 secretion in the latter mutant by stepwise addition of each of the EPTP domains from one to six, using the scheme described in (15) . Only the intact wild-type protein that contains all seven EPTP domains was secreted from cells.
Secretion of LGI1, but not N-glycosylation, is blocked by ADLTE-causing mutations
We next assessed whether naturally occurring mutations in LGI1, which cause ADTLE, alter the secretion or glycosylation of the protein. HEK293T . All of these constructs resulted in robust LGI1 expression but only LGI1-Flag LONG accumulated in media, indicating that the naturally occurring 
LGI1, which cause disease, do not exit the cell, regardless of whether they were truncating or missense mutations (Fig. 4B) . We also examined the sensitivity of these proteins to the PNGase F treatment and found, despite these trafficking defects, that all the LGI1 mutants tested were N-glycosylated (Fig. 4C ).
Subcellular localization of LGI1
To determine the subcellular localization of LGI1-GFP LONG , LGI1-GFP SHORT and ADLTE-related mutants LGI1-GFP 758delC , LGI1-GFP R474X , LGI1-GFP F318C and LGI1-GFP E383A , COS7 cells were transiently transfected with each construct and transfected cells were immunostained with an antibody recognizing calnexin, an endoplasmic reticulum resident protein, or labelled with the fluorescent Golgi marker Bodipy TR ceramide. Confocal analysis revealed that LGI1-GFP LONG is enriched in the Golgi apparatus, whereas LGI1-GFP SHORT and the mutants analyzed, excluding LGI1-GFP R474X , accumulate in the ER chaperone.
LGI1-GFP R474X is present in both ER and Golgi (Fig. 5) . Colocalization of LGI1 and the ER was also demonstrated by co-immunoprecipitating the wild-type and the mutant constructs with an antibody that recognizes calnexin (data not shown).
LGI1 binds to the surface of PC12 cells Because LGI1 is secreted to the extracellular medium, we assessed whether LGI1 could specifically interact with cell surface proteins. For this, we prepared conditioned media containing either placental alkaline alone or placental alkaline phosphatase fused to LGI1 LONG (AP-LGI LONG ) and compared these for their ability to bind NGF-differentiated PC12 cells as well as to the surface of non-differentiated PC12 and COS7 cells (data not shown). Figure 6 shows the highly specific, dose-dependent and saturable binding of AP-LGI LONG , with half-maximal binding observed at a concentration of 4 nM, suggesting that specific LGI1 receptor complex is present on these cells.
Binding of AP-LGI1 to the cell surface results in reduction of activated ERK1/2
To determine the effect that AP-LGI1 binding had on the cells, we assessed the activation state of ERK1/2, as it has been shown that overexpression of LGI1 caused a decrease in their activated levels in T98G cells (21) . Figure 7 shows that incubating NGF-differentiated PC12 cells with AP-LGI1 LONG results in a significant reduction in the level of activated ERK1/2 when compared with AP-treated cells.
DISCUSSION
We demonstrate here that LGI1 is a glycoprotein secreted to the extracellular media in several in vitro models including a neuronal-like cell type. The shorter and much less prevalent spliced isoform is retained within the cell. This is true even though the short isoform is expressed at higher levels in our in vitro system. In some instances, usage of alternative splice sites within coding exons has been shown to produce isoforms with different, even opposite, functions (22, 23) ; thus, the existence of two LGI1 isoforms with different cellular locations suggests that these proteins may have different functions.
LGI1 is the gene responsible for ADLTE, and distinct mutations have been described in several families. Diseasecausing LGI1 mutations have been identified throughout the LGI1 open reading frame (3,4,6 -11,24) , and in this study, we have tested the hypothesis that disease-causing mutations alter LGI1 secretion. We show here that each of the disease-causing forms of LGI1 are defective in secretion from transfected cells. We did not detect changes in the glycosylation of the mutant proteins, but instead demonstrate that the mutant proteins are largely retained in the endoplasmic reticulum. The only exception was LGI1-Flag
R474X
, which was present in both in the endoplasmic reticulum and the Golgi apparatus. This mutation produces a truncated protein lacking the C-terminal 83 amino acids, and it is possible that it retains structural elements that allow it to partially mimic the normal protein and reach the Golgi apparatus. Using artificial mutations, we also show that the LRR domain is not required for secretion, but that an intact EPTP domain with all seven tandem repeats is required for the protein to exit the cell, and find that N-linked glycosylation of LGI1 is necessary for its secretion, but individual mutation of any of the three putative N-linked residues does not block its exit from the cell. We conclude that the disease-related missense mutations are exerting their effect by altering the tertiary structure of the protein, causing their retention and degradation through protein quality control mechanisms.
The secretion of the full-length isoform together with the retention of the spliced isoform also raises interesting showed that when T98G cells were forced to re-express the long isoform, the malignancy of this glioma cell line was severely reduced, and this correlated with reduced ERK1/2 phosphorylation and reduced metalloproteinase production.
Given that, we have demonstrated that LGI1 binds in a dosedependent manner to differentiated PC12 cells and that this binding has a functional effect in the cells. It is possible that forced overexpression of LGI1 in T98G cells may have activated a ligand-receptor autocrine loop in these cells, which altered cellular signalling pathways. Schulte et al. (20) have recently shown that LGI1 is part of a Kv1 channel complex and provided evidence that LGI1 acts to prevent the inhibitory effect of the Kvb1 channel subunit. They report that mutant forms of LGI1 assemble into Kv1 channel complexes yet are incapable of altering the Kvb1 channel inhibitor activity. They propose that the C-terminal domain of LGI1 lost in truncated mutants of the protein is required for the Kvb1 channel antagonizing activity. We show here that a major consequence of LGI1 mutation is ER retention and a failure to enter the Golgi and the secretory pathway. Therefore, an equally plausible alternative explanation for the findings of Schulte et al. (20) is that the mutant LGI1 assembles into Kv1 complexes in the ER and the resulting assembly remains trapped in this compartment. In this scenario, only the Kv1 complexes lacking LGI1 would actually reach the cell surface.
Taken together, our data suggest a hypothesis for the molecular pathology of ADLTE based on the retention of LGI1 in intracellular compartments. This retention could have a gain of function with cell autonomous effects, such as on Kv1 channels, or could result in a lost of function from non-autonomous effects that include the loss of a critical cell communication between cells that secrete LGI1 and cells that respond to it.
MATERIALS AND METHODS

Constructs
Several constructs were prepared for this work as fusion proteins. Proteins fused to GFP were cloned into pEGFP-N1 (Clontech), proteins fused to AP were cloned into pc3.1AP6 and fusions to the Flag epitope were cloned into pSalo-Flag, a modified version of pEGFP-N1 with the GFP protein removed and substituted by a Flag epitope. For simplicity, each construct is named by placing the name of the tag showing its position with respect to the cloned LGI1.
Both LGI1 isoforms, the full-length (long, amino acids 1 -557) and the splicing variant (short, amino acids 1-259), were cloned from a human cDNA library (Invitrogen). For this study, we have selected mutations producing truncated proteins [c.758delC and p.R474X (3)] and some missense mutations affecting different domains of the protein: the Nterminal cysteine-rich domain [p.C46R (24) ], the third leucine-rich repeat [p.S145R (10) ], the C-terminal cysteine-rich domain [p.C200R (8) ] and the third and fourth EPTP repeats [p.F318C (6) and p.E383A (4), respectively]. In addition to these, we have also introduced the mutations affecting the three potential N-glycosylation sites predicted by NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/), p.N192Q, p.N277Q and p.N422Q. Finally, we have created two deletion constructs: one lacks the EPTP-repeat region (DEPTP, lacking amino acids 224-556) and one lacks the LRR region (DLRR) and contains the signal peptide (amino acids 1 -34) fused to the EPTP-repeat region (amino acids 224 -556). In addition to those, we have produced several chimeric forms lacking part or all of a particular domain, as shown in Figures 1-3 . For the serial deletions of the EPTP repeats, different primers were used in order to obtain seven constructs containing from 0 to 6 EPTP repeats tagged with Flag: 0EPTPs (ending at amino acid 223), 1EPTP (ending at 267), 2EPTPs (ending at 314), 3EPTPs
(ending at 364), 4EPTPs (ending at 415), 5EPTPs (ending at 462) and 6EPTPs (ending at 506). To obtain the AP-LGI1 vector, the cDNA encoding amino acids 35 -557 was ligated into the pc3.1AP6 vector in frame with signal sequence and placental AP coding region. All mutagenesis were done with the Quick Change Mutagenesis kit (Stratagene), and all constructs generated by PCR were fully sequenced to ensure integrity of the cloned ORFs. All primers used as well as PCR conditions are available from the authors on request. Human
Cell culture, transient transfection and media collection CHO, COS7 and HEK293T cells were grown in DMEM (Cambrex), supplemented with 10% (v/v) heat inactivated foetal bovine serum (FBS, Gibco), 2 mM glutamine (Gibco) and 2% (v/v) penicillin/streptomycin (10 000 U/ml penicillin and 10 mg/ml streptomycin; Gibco) on 10 cm plates and maintained at 378C and 5% CO 2 . T98G cells, a glioblastomaderived cell line that does not express LGI1 (12), were grown in DMEM (Cambrex), 10% (v/v) FBS, 2 mM glutamine, 1% non-essential amino acids (Gibco) and 1% sodium pyruvate (Gibco). PC12 cells were grown on poly-D-lysine coated plates in EMEM supplemented with 2 mM glutamine, 2% (v/v) penicillin/streptomycin and 0.1% BSA. When required, PC12 cells were differentiated with 50 ng/ml NGF in complete medium for 48 h. T98G, COS7 and CHO cells were transiently transfected with liposomes (Fugene, Roche), and HEK293T were transfected by the calcium phosphate method. PC12 cells were transfected with lipofectamine and differentiated with NGF 24 h post-transfection. For media production, HEK293T cells were grown to~60 -70% confluence and were transiently transfected with 5 mg DNA. After 16-20 h of transfection, the media were replaced with a reduced serum media (Optimem I, Gibco) and incubated for an additional 24 h. Then, media were collected, supplemented with a protein inhibitor cocktail (Complete, Roche), filtrated through a 0.2 mm filter and concentrated 10 -15 times to 300 ml using an Amicon Ultra15 device (MWCO: 30 000 kDa; Millipore) and analysed by SDS -PAGE.
For binding experiments, after 2 days on serum-free DMEM, secreted AP-LGI1 and AP were first concentrated as before and then the amount of protein was estimated according to (25, 26) , measuring the AP activity using pnitrophenyl phosphate as substrate (Sigma). For the binding experiments, the concentrated media were diluted with PBS 1Â medium to 5-40 nM.
SDS -PAGE and western blotting
Equivalent volumes of concentrated media and immunoprecipitates were loaded onto 10% SDS -PAGE gels to resolve proteins. Following transfer, nitrocellulose membranes (Amersham) were blocked at room temperature for 1 h with non-fat dry milk powder in Tris-HCl, 20 mM, pH 7.6, NaCl 140 mM and Tween-20 0.1% (v/v) (TBST) to reduce non-specific Immunoprecipitation and pulse-chase analyses HEK293T cells were lysed and scraped in 1 ml NP-40-containing lysis buffer (10 mM Tris -HCl, pH 8, 150 mM NaCl, 1% NP-40, 10% glycerol, 1% Triton X-100 and protease inhibitors) for 30 min at 48C. Cell lysates were clarified by centrifugation at 13 000 r.p.m. at 48C for 10 min and then the supernatants were incubated with protein G Sepharose beads (Amersham) conjugated with M2 mouse antiFlag antibody (Sigma) at 48C for 2 h. The beads were washed three times with lysis buffer and then resuspended in 60 ml 2Â Laemmli sample buffer for SDS -PAGE. For pulse-chase analyses, cells were transfected with LGI1 or parental vector and 24 h later, pre-incubated in cysteine-and methioninefree media for 30 min, followed by incubation for 30 min in labelling media consisting of 50 mCi/ml 35 S-Trans-label (ICN) and 3 mg/l unlabelled cysteine and methionine, respectively, for 30 min. Cells were then switched to normal media (30 mg/l cysteine and 30 mg/l methionine) for 10, 30 or 60 min. After lysis, immunoprecipitations were performed using monoclonal anti-Flag antibodies. Immunoprecipitates were separated by SDS -PAGE, gels were impregnated with Enhance (NEB) and dried, using the protocol provided by the manufacturer.
PNGase F digestion
Cell lysates and culture medium obtained as described from transiently transfected HEK293T cells were immunoprecipitated as mentioned earlier and resuspended and denatured in 25 ml of denaturing buffer at 1008C for 10 min and cooled to room temperature. The denatured samples were subjected to digestion with 4 mU of PNGase F (New England Biolabs) at 378C for 90 min. The samples were then analysed by SDS -PAGE.
Subcellular localization of wild-type and mutant LGI1
Twenty-four hours after transfection with the LGI1-GFP constructs using FuGene (Roche), COS7 cells grown on glass cover slips were fixed with 4% (w/v) paraformaldehyde in PBS at 378C for 30 min. Slides were blocked at room temperature for 2 h with 5% BSA in PBS and then immunostained with the ER marker anti-calnexin (1:500, Calbiochem) at 48C overnight. Slides were washed and incubated with Texas Red-conjugated anti-rabbit antibody (1:5000, Molecular Probes) at room temperature for 2 h. Alternatively, COS7 cells were incubated with the Golgi marker Bodipy TR Ceramide (Molecular Probes) at a 3 mM concentration in culture media for 30 min at 378C. Images were collected on a Leica TCS SL Spectral Confocal Microscope coupled to an inverted microscope (Leica DMIRE2; Leica Microsystems) at room temperature with a 63Â immersion objective (HCX PLAPO CS, 63Â/1.40 -0.60. Images were captured on a computer system by the Leica Confocal Software v2.5 (Build 1347, Leica Microsystems).
Cell-binding assays of AP fusion proteins
AP-tagged fusion proteins were produced by transient transfection of HEK293T cells with either AP-LGI1 or empty vector producing secreted AP. PC-12 cells, 5 Â 10 5 cells/well, were plated in 6-well plates coated with poly-D-lysine and differentiated with NGF (50 ng/ml) for 48 h. Afterwards, plates were washed twice with PBS 1x and then cells were incubated with dilutions of either AP or AP-LGI1 for 90 min at 378C. Cultures were then washed three times with ice-cold Hanks balanced salt solution containing 20 mM sodium HEPES, 0.1% sodium azide and 0.5 mg/ml BSA. Plates, where the binding was quantified, were processed with lysis buffer (20 mM Tris -HCl, pH 8.0, 0.1% Triton X-100 and protease inhibitors). Endogenous AP activity was heat inactivated at 658 for 15 min and bound AP activity was assessed using p-nitro phenyl phosphate as substrate measuring absorbance at 405 nm. In order to normalize the results, total protein present in the lysates was measured by DC protein assay (Bio-Rad). Plates, where pictures were taken, were incubated at 658 for 90 min to heat-inactivate the endogenous AP activity, and the AP-LGI1 binding was revealed in the presence of nitro blue tetrazolium and BCIP (5-bromo-4-chloro-3-indolyl phosphate) (Sigma).
Determination of ERK1/2 levels
Conditioned media from HEK293T cells expressing either AP-LGI1 LONG or the AP alone were incubated with NGF-differentiated PC12 cells for the times shown in Figure 7 at 378C, normalizing for the AP activity at 15 nM. As the process of differentiation of the PC12 cells by NGF requires activation of the ERK1/2 pathway, and the incubation with conditioned media could affect the state of activation of ERK1/2 by itself, we pre-treated all cultures with an equivalent amount of conditioned media coming from mock-transfected HEK293T for 2 h prior to AP-LGI1 LONG or AP treatment. After treatment, the cells were washed with PBS and harvested in RIPA buffer (1.5 M NaCl, 1% NP-40, 0.5% deoxycholate, 1% SDS, 50 mM Tris -HCl, pH 8.0) with a cocktail of protease inhibitors (Complete, Roche) supplemented with 1 mM sodium orthovanadate. Cell lysates were incubated on ice for 30 min prior to clarification at 48C and 16 000g for 15 min. An aliquot of 15 mg of protein from each condition was assayed by western blotting using an antibody that recognizes phosphorylated ERK1/2. After stripping of the blot, it was incubated with a phosphorylation-independent antibody that recognized total ERK1/2. In both cases, the western blotting was developed and an image was captured and the intensity of each band was measured with the help of the MultiGauge v2.1 software (Fujifilm). After this, we estimated the relative amount of phospho-ERK1/2 over total ERK1/2.
